Khellin

Drug Profile

Khellin

Alternative Names: Khelline; Khellinum; KUVA; Visammin

Latest Information Update: 09 Nov 2006

Price : $50

At a glance

  • Originator Ardeypharm; Loges; Nonindustrial source
  • Class Antiasthmatics; Bronchodilators; Ischaemic heart disorder therapies; Psoralens; Small molecules; Vasodilators
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Cardiovascular disorders
  • Discontinued Alopecia; Vitiligo

Most Recent Events

  • 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in South Africa (Topical)
  • 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in Bulgaria (Topical)
  • 22 Sep 2000 No-Development-Reported for Vitiligo in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top